{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"100 mg Tabalumab+Dexamethasone+Bortezomib compared with Placebo Comparator: Placebo + Dexamethasone + Bortezombib, only tabalumab odds ratio compared to placebo.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.401","paramType":"Odds Ratio (OR)","paramValue":"1.98","statisticalMethod":"Regression, Logistic"},{"ciNumSides":"TWO_SIDED","groupDescription":"300 mg Tabalumab+Dexamethasone+Bortezomib compared with Placebo Comparator: Placebo + Dexamethasone + Bortezombib, only tabalumab odds ratio compared to placebo.","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.455","paramType":"Odds Ratio (OR)","paramValue":"1.84","statisticalMethod":"Regression, Logistic"},{"ciNumSides":"TWO_SIDED","groupDescription":"100 mg Tabalumab+Dexamethasone+Bortezomib and 300 mg Tabalumab+Dexamethasone+Bortezomib compared with Placebo Comparator: Placebo + Dexamethasone + Bortezombib, only compared to placebo.","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.419","paramType":"Odds Ratio (OR)","paramValue":"1.90","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}],"title":"Stringent Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"9"}]}],"title":"Very Good Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"29"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}]}],"title":"Minimal Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"72"}],"units":"Participants"}],"description":"Response categories in order of decreasing quality are: Stringent Complete Response(sCR),Complete Response(CR), Very Good Partial Response(VGPR),Partial Response(PR),Minimal Response(MR),Stable Disease(SD), or Progressive Disease(PD), according to the International Uniform Response Criteria for Multiple Myeloma.SCR:normal free light chain ration and no clonal cells in bone marrow;CR-no monoclonal protein(mp) in blood, no serum/urine,\\<5% plasma cells in bone marrow; VGPR-more than 90% decrease in mp and urine protein; PR-\\>50% decrease in serum MP;SD-\\<25% decrease in mp; PD-25% increase compared to lowest value of serum mp, urine mp and no measurable mp.","groups":[{"description":"Tabalumab 100 milligram (mg) administered once intravenously (IV) over 30 minutes on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 milligram per square meter (mg/m\\^2) administered once subcutaneously (SQ) on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG000","title":"100 mg Tabalumab+Dexamethasone+Bortezomib"},{"description":"Tabalumab 300 mg administered once IV over 30 minutes on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 mg/m\\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG001","title":"300 mg Tabalumab+Dexamethasone+Bortezomib"},{"description":"Placebo administered once IV on Day 1 every 21 days for 8 cycles.Placebo administered once IV on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 mg/m\\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG002","title":"Placebo Comparator: Placebo + Dexamethasone + Bortezombib"}],"paramType":"NUMBER","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline to Objective Disease Progression or Initiation of New Cancer Treatment (up to 28 Months)","title":"Number of Participants With a Given Best Objective Myeloma Response (Quality of Response [QoR])","type":"SECONDARY","unitOfMeasure":"participants"}